Filed under: Earnings reports, Options

GlaxoSmithKline (NYSE: GSK) is recently down $3.75 to $42.13.

GSK reported a declining Q4 pre-tax profit and warned 2008 earnings will be negatively affected by decreasing sales of diabetes drug Avandia, competition from generics and a weak dollar.

GSK overall option implied volatility of 26 is near its 26-week average according to Track Data, suggesting non-directional risk.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Permalink | Email this | Comments

Share This

This entry was posted on Thursday, February 7th, 2008 at 9:05 pm and is filed under Stocks Money News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.